Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia-Reference-Cited by-同舟云学术

Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia

Published:2019-08 Issue:8 Volume:25 Page:1550-1559
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Schroeder Thomas,Wegener Nadija,Lauseker Michael,Rautenberg Christina,Nachtkamp Kathrin,Schuler Esther^ORCID,Kondakci Mustafa^ORCID,Haas Rainer,Germing Ulrich,Kobbe Guido

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference38 articles.

1. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel;de Witte;Blood,2017

2. The current and future role of stem cells in myelodysplastic syndrome therapies;Kobbe;Exp Rev Hematol,2018

3. Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?;de Witte;Clin Lymph Myel Leuk,2014

4. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial;de Witte;Haematologica,2010

5. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS;de Witte;Blood,2001

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current challenges in conditioning regimens for MDS transplantation;Blood Reviews;2024-09

2. Place de l’allogreffe dans les leucémies aiguës myéloblastiques et syndromes myélodysplasiques de très haut risque (SFGM-TC);Bulletin du Cancer;2024-09

3. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

4. Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome;Bone Marrow Transplantation;2024-07-09

5. WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients;Annals of Hematology;2024-07-06